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Risk stratifiers for arrhythmic and 
non-arrhythmic mortality after 
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Alfonso M. Gañán-Calvo  1, Katerina Hnatkova2, Álvaro Romero-Calvo  3, Juan Fajardo-
López4 & Marek Malik2
The effective discrimination between patients at risk of Arrhythmic Mortality (AM) and Non-Arrhythmic 
Mortality (NAM) constitutes one of the important unmet clinical needs. Successful risk assessment 
based on Electrocardiography (ECG) records is greatly improved by the combination of different 
indices reflecting not only the pathological substrate but also the autonomic regulation of cardiac 
electrophysiology. This study assesses the cardiac risk stratification capacity of two new Heart Rate 
Variability (HRV) parameters, Breath Concurrence 6 (BC6) -sinusoidal RR variability of 6 heart beats 
per breath cycle- and Primary Ectopia (PE) -presence of early ventricular contractions of any etiology- 
together with the Deceleration Capacity (DC). While BC6 characterizes the response to physiological 
and pathophysiological stimuli, PE qualifies autonomic cardiac electrophysiology. The analysis of the 
European Myocardial Infarct Amiodarone Trial (EMIAT) database indicates that BC6 is related with the 
risk of Arrhythmic Mortality (AM) and PE with the risk of Non-Arrhythmic Mortality. BC6 is the only 
single parameter that significantly discriminates between AM and NAM. While the combination of BC6 
and DC contributes to the identification of AM risk, PE together with DC improves the prediction of 
NAM in patients with severe ischemic heart disease.
Identification of patients at increased risk of death is a multifactorial process. It depends not only on factors that 
cannot be modified, such as age, sex, comorbidity, and the injury severity, but also on factors that might be altered 
by disease progression, treatment delay, and therapeutic effects on the target organ and on the whole organism.
The problem of mortality stratification among cardiac patients also involves the distinction between the risk 
of Arrhythmic Mortality (AM) and Non-Arrhythmic Mortality (NAM)1. Patients at increased risk of AM might 
benefit from Implantable Cardioverter Defibrillators (ICD) although not all AM are preventable by ICD inter-
ventions. On the contrary, ICD therapy is less likely effective in patients at increased risk of NAM. However, the 
present guidelines for the selection of candidates for ICD implantation are based on low Left Ventricular Ejection 
Fraction (LVEF) and do not make much distinction between AM and NAM risk2.
This is now well recognized and effective: identification of patients at risk of AM rather than of NAM con-
stitutes one of the important unmet clinical needs3. Multiple studies aimed at addressing this need and involved 
a variety of non-invasive risk profiling techniques. A consensus emerges from these studies that successful risk 
assessment of cardiac patients needs to involve combination of different indices reflecting not only the patholog-
ical substrate but also autonomic regulation of cardiac electrophysiology4.
To contribute to the development of multifactorial risk assessment in cardiac patients, we present a combi-
nation of a newly developed Heart Rate Variability (HRV) assessment mode5 with Deceleration Capacity (DC)6, 
which is one of the most powerful risk predictors based on HRV principles. We aim at demonstrating that even 
within the HRV framework, combination of different indices may advance the field of cardiac risk stratification 
meaningfully.
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Methods
Population and long-term electrocardiographic recordings. To evaluate the differences in AM and 
NAM risk prediction based on HRV assessment, data of cardiac patients with objective distinctions between dif-
ferent mortality modes are needed. For this purpose, we used the database of the previously conducted European 
Myocardial Infarct Amiodarone Trial (EMIAT)7 which enrolled post-Myocardial Infarct (MI) patients with LVEF 
not exceeding 40% and randomized these to placebo and prophylactic amiodarone treatment.
The EMIAT trial was appropriately ethically approved and all participants gave informed consent which 
included further research use of their data. The trial patients were followed up for 2 years (median follow-up of 
21 months) and all death cases were classified as non-cardiac (e.g. due to malignancies), cardiac non-arrhythmic 
(e.g. due to slow progression of heart failure) and cardiac arrhythmic. The classification was performed by a 
dedicated committee of the trial and the classifications were available for the purposes of the present study. All 
methods were performed according with the approved guidelines and regulations described by Julian et al.7.
The combination of the new HRV method with DC was tested in the placebo part of the EMIAT trial. Per pro-
tocol, 24-hour Holter recordings were obtained in all trial patients. In addition to these Holter recordings, LVEF 
measurements in the patients were also available for the purposes of the present investigation.
In all Holter recordings, detailed sequences of RR intervals including the distinction between sinus-nodal and 
ectopic beats were available as previously described. The data of DC measurement in the recordings (as briefly 
described further) were available from previous analyses of the parameter.
The novel HRV indices were evaluated by the University of Seville team without any access to the follow-up 
data. The follow-up data were kept by the Imperial College London team who were involved in the evaluation of 
the indices calculated by the Sevilla team but were kept blinded in terms of the nature of the novel HRV indices.
Assessment of deceleration capacity. DC values were obtained by means of the previously described 
technology6. Briefly, the DC index was calculated using the following steps:
 1. Definition of the anchors: RR intervals longer than the preceding interval are identified as anchors.
 2. Definition of segments: Segments are defined as RR interval vectors around the anchors. All segments 
have the same size, chosen according to the lowest frequency to be visualized.
 3. Phase rectification: All segments are aligned with the anchors as reference point.
 4. Signal averaging: A X(i) signal is obtained by averaging the segments. X(0) is the average of the RR inter-
vals at the anchors, X(1) is the average of the RR intervals immediately following the anchors, X(−1) is the 
average immediately preceding the anchors, etc.
Figure 1. Synthetic Electrocardiography (ECG) curves showing (a) a PE example outside tolerance and (b) a 
BC6 example inside tolerance. The components of vector δi are calculated according to equation (2), while θi is 
given by equation (7).
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 5. Quantification of DC: The DC coefficient is obtained as
= + − − − − .DC X X X X1
4
[ (0) (1) ( 1) ( 2)] (1)
Assessment of Breath Concurrence and Primary Ectopia. The novel HRV assessment was based on 
previously described principles5, summarized as follows. A Holter Record RR report is here treated as a set of M 
consecutive values corresponding to the measured RR intervals, that can be expressed as X{ }i i M1, ,= ... . To perform 
a study of the existence of universal HRV sequences and their appearance, the record can be represented as a 
locally normalized set of consecutive vectors
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where N is the length of the sequence to be analyzed, and X N Xi N jN i j,
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+  is the local average5. In this 
work, while the average is taken for N subsequent beats, only N − 1 components of δi are considered, since the 
Nth-component of iδ  would equal the sum of the first (N − 1) ones according to the local normalization made. 
LVEF [%] DC PE BC6
Survivors 30.55 ± 7.28 4.69 ± 3.55 0.79 ± 2.27 1.04 ± 0.63
All-Cause Mortality 26.52 ± 7.91 2.25 ± 4.41 1.81 ± 3.01 0.87 ± 0.62
p-value S vs ACM <0.0001 <0.0001 0.0031 0.0224
Non-Arrhythmic Mortality 24.84 ± 8.61 2.68 ± 3.25 2.21 ± 3.71 1.06 ± 0.61
p-value S vs NAM 0.0008 0.0019 0.0395 0.8371
Arrhythmic Mortality 26.88 ± 7.53 1.53 ± 5.43 1.55 ± 2.71 0.76 ± 0.62
p-value S vs AM 0.0033 0.0005 0.0782 0.0071
p-value NAM vs AM 0.1873 0.2132 0.4566 0.0296
Table 1. Comparison of LVEF, DC, PE, and BC6 between patients who survived (S) during the follow-up and 
those who died (ACM, AM, NAM).
Figure 2. Progression of mortality risk when stratifying high risk patients based on the coefficients DC, LVEF, 
PE and BC6.
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This normalization supposes an important step to analyze the presence of characteristic structures among indi-
viduals, independently of their average beat rate or instantaneous activity. Among the infinite diversity of possible 
structures, a limited number has been observed in real records5. Ones of the most common structures found are 
lines that pass through the origin of coordinates. Thus, it is possible to define the simplest universal sequence as a 
line in an (N−1)-dimensional space of the form
A a a a t{ , , , } , (3)N1 2 1= ... −
parametrized by a variable t representing the severity of heart rate variability.
Two sequences of this form were defined on a previous publication, where the first one is given by
= −B t1 { 1, 1, 0, 0} , (4)5
and represents an ectopic beat which produces an early beat (−1)t followed by a beat delayed by an increment in 
time twice as wide as the advance in previous beat (+1)t, and two subsequent regular beats (0). Note that t times 
the corresponding component of the vector is the normalized time difference found between the corresponding 
beat and the average of the interval (the base of normalization). The majority of ectopic beats siting around B15 
had ventricular origin.
The second sequence is defined by
j
N
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and reflects the modulation of breath on heart rate variability. This sequence assumes that a complete breath 
cycle takes approximately N heart beats. A previous study has shown that the presence of this sequence is approx-
imately maximized for N = 6 in healthy individuals5, a value which is assumed for this study. Hence, the corre-
sponding sequence is
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The projection of the δ vectors on those sequences makes it possible to define the generalized deviation angles
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Figure 3. Separate progression of mortality risk when stratifying high risk patients based on the population 
subgroups with lower DC, LVEF, PE and BC6 coefficients.
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where “·” denotes the scalar product of two vectors, ||  || their module, and |  | the absolute value. The quantity
A
A (8)
i
i
δ
δ
⋅
⋅
can also be understood as the Pearson correlation coefficient between the real and the predetermined heart beat 
sequence.
Figure 4. Stratification of DC, PE and BC6 coefficients at one third of the data for (a) ACM, (b) NAM and (c) 
AM. Label indicates the color codes for each group considered. High Risk group is the 33% highest mortality 
one, while Low Risk group is the 66% lowest mortality one.
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The presence of events (% of sequences) where the deviation angle θi is below a predetermined level θmax is a 
coefficient which measures the occurrence of the corresponding sequence, i.e.:
∑ θ θ= ⋅ ≤ .
=
P
M
(%) 100 1 (1 if ; 0 otherwise)
(9)i
M
i max
1
We performed a blind-blind analysis where the two previous parameters were calculated for each individual. 
A tolerance of θ = .0 05max ,1  was selected for the calculation of the presence of B15, while θ = .0 2max ,2  was set for 
Breath6. The choice of these tolerances for each sequence was based on a selection not influenced by subsequent 
results, and therefore subject to further optimization. In this work, that choice was based on a statistical analysis 
both intra-sample and among samples:
 1. Each individual shows an increasing presence of points (vectors) around the corresponding sequence as 
the volume defined by the angle θ increases, until a first plateau at θtp is reached. Above that turning point 
θtp, the number of vectors that fall inside the volume defined by θ > θtp, increases at a significantly smaller 
pace. That turning point θtp is rather sharp in about 90% of individuals with a presence of the correspond-
ing sequence above 10% (“positives”).
 2. Since θtp varies among individuals, we selected an approximate overall value θmax below 0.25 and above 
the average θtp of the 90% of positives with smaller θtp, corresponding to that around which the number of 
positives presented a minimal variation.
From now on, the presences of B15 and Breath6 with selected tolerances θmax ,1 and θmax ,2 will be called Primary 
Ectopia (PE) and Breath Concurrence 6 (BC6), respectively. A conceptual scheme of the calculation process is 
given in Fig. 1.
These coefficients were calculated by the research group in Sevilla, Spain, based solely on the sequences of 
normal-to-normal RR intervals in the long-term EMIAT trial Holter records. We emphasize that the research 
group in Sevilla was (and still is) fully blinded in terms of the identity, clinical characteristics, and follow-up 
outcome of individual EMIAT patients. On the contrary, while performing the statistical analyses, the research 
group in London, England, was fully blinded in terms of the principle and calculations of the detailed indexes.
Given the nature of our blind-blind analysis here reported, the two tolerances θmax ,1 and θmax ,2 were not opti-
mized to provide the highest significance in the results per se. A subsequent study analyzing the sensitivity of the 
significance of the results to these tolerances shall be performed in the future.
Statistics and data presentation. Where appropriate, data are presented as mean ± standard deviation. 
Comparisons of LVEF, DC, PE, and BC6 were made between survivors and patients who, during the follow-up, 
died of All Cause Mortality (ACM), NAM, and AM. Two-sample two-tail t-test assuming unequal variances were 
used for this purpose.
Firstly, the risk prediction by LVEF, DC, PE, and BC6 were compared univariately including the dependency 
of mortality modes on the distribution of these indices. For this purpose, the complete study population was 
sorted according to each of the indices. The mortality (including the proportion between AM and NAM) was 
Model 1 p-value
LVEF
p-value
DC
p-value
PE
HR HR 95% CI HR HR 95% CI HR HR 95% CI
ACM
<0.001 0.950 0.926–0.975 <0.001 0.921 0.882–0.962 0.834 1.007 0.946–1.071
0.032 0.626 0.408–0.959 <0.001 0.272 0.168–0.441 0.075 0.664 0.432–1.042
NAM
<0.001 0.924 0.886–0.963 0.523 0.969 0.881–1.066 0.195 1.072 0.965–1.190
0.019 0.424 0.207–0.869 0.020 0.397 0.182–0.866 0.061 0.484 0.227–1.035
AM
0.030 0.959 0.924–0.996 <0.001 0.891 0.848–0.936 0.408 0.961 0.874–1.056
0.263 0.707 0.386–1.297 <0.001 0.161 0.078–0.335 0.882 0.953 0.508–1.790
Model 2 p-value
LVEF
p-value
DC
p-value
BC6
HR HR 95% CI HR HR 95% CI HR HR 95% CI
ACM
<0.001 0.950 0.926–0.975 <0.0001 0.928 0.894–0.964 0.210 0.784 0.536–1.147
0.024 0.611 0.398–0.938 <0.001 0.251 0.159–0.397 0.022 0.608 0.398–0.930
NAM
<0.001 0.927 0.889–0.966 0.026 0.925 0.863–0.991 0.408 1.266 0.724–2.212
0.018 0.419 0.204–0.860 0.001 0.304 0.146–0.634 0.993 0.997 0.477–2.081
AM
0.021 0.957 0.922–0.993 0.001 0.921 0.878–0.967 0.080 0.590 0.327–1.065
0.234 0.691 0.376–1.270 <0.001 0.177 0.088–0.357 0.010 0.451 0.246–0.826
Table 2. Statistical significances of Cox proportional hazard models. For each risk stratifier and for each 
follow-up outcome, the top line of the results shows the results of Cox proportional hazard models applied 
to continuous numerical data while the bottom line (in italics) shows the results of the models applied to the 
parameters dichotomized at one third of the population (not optimized for either PE or BC6 yet). P-values 
are shown together with Hazard Ratios (HR) and with their 95% Confidence Intervals (CI). The bold results 
indicate statistical significance at p < 0.05.
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evaluated in different parts of the population ranging from 10% of the highest risk patients (according to the given 
index) up to 100% of the complete population. These dependences were compared graphically.
Subsequently, mortality prediction by LVEF, DC, PE and BC6 was tested by multivariate Cox regression 
model. Two different variants of the model were used, one using a combination of LVEF, DC, and PE; the other 
using a combination of LVEF, DC, and BC6. These Cox models were performed for ACM, NAM, and AM.
Figure 5. Survival curves for the combinations (DC + PE), (DC + BC6) and (PE + BC6) when using the 33% 
dichotomies for (a) ACM, (b) NAM and (c) AM. Label indicates the color codes for each two-groups of the 
combination considered. High Risk group is the 33% highest mortality one, while Low Risk group is the 66% 
lowest mortality one.
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Finally, to concentrate on the assessment based on the Holter analyses, a dichotomy of DC, PE, and BC6 was 
found selecting (for each of these indices) one third of the patients with the highest risk of ACM. Probability 
of ACM, NAM and AM was compared between the dichotomized parts of the population as well as for a com-
bination of the dichotomized parts by two of the indices using Kaplan-Meier survival curves. Cases of two 
Kaplan-Meier curves were compared by log-rank tests; cases of more curves were compared by chi-square tests.
Statistical evaluations were made using SPSS Statistics package release 24.0.0.1. P-values below 0.05 were con-
sidered statistically significant.
Results
Population and survival data. Holter recordings were available in 634 of EMIAT patients randomized 
to the placebo group. During the 2-year follow-up of the trial, 87 of these patients died. Of these cases, 12 were 
non-cardiac (e.g. due to malignancies), 32 were cardiac non-arrhythmic (e.g. due to slow progression of heart 
failure), and 43 were cardiac arrhythmic mortalities. The application of the previously defined coefficients to the 
placebo patients of the EMIAT database results in a 634 × 2 matrix of values which are subsequently analyzed.
Univariate risk prediction. Table 1 shows the comparison of the evaluated indices in patients who survived 
during the follow-up period and those who died, including ACM, NAM and AM cases. The table shows that sim-
ilar to LVEF and DC, the PE and BC6 parameters were statistically significantly different between survivors and 
non-survivors, increased values of PE were predominantly found in patients at risk of (counterintuitively) NAM 
while decreased values of BC6 were predominantly found in patients at risk of AM. Of all the investigated param-
eters, BC6 index was also the only one that statistically significantly differed between patients who subsequently 
succumbed to NAM and AM.
As shown in Table 1, compared to survivors, patients at increased mortality risk had smaller LVEF, smaller 
DC, larger PE, and smaller BC6.
Figures 2 and 3 consequently show the mortality levels in different subgroups of high risk patients – i.e. 
patients with smallest LVEF, DC or BC6 and largest pe, respectively. While Fig. 2 shows the different mortality 
modes cumulatively, Fig. 3 shows the mortality strata separately. The comparisons of the risk stratifiers shown in 
Figs 2 and 3 are in agreement with the statistical evaluations presented in Table 1. In particular, Fig. 3 shows that 
the increase of mortality risk among patients with the smallest values of BC6 is almost exclusively caused by an 
increase of AM.
The univariate Kaplan-Meier curves of the probabilities of death stratified according to DC, PE, and BC6 are 
shown in Fig. 4. In each of the cases, one third of the populations at high risk of ACM is compared to the two 
thirds of the population at lower risk of ACM.
The graphs in Fig. 4 suggest that while PE is comparable to DC in terms of the prediction of NAM, BC6 is 
comparable to DC in terms of the prediction of AM.
Multivariate risk prediction. Table 2 shows the significances of the two Cox proportional hazard models 
based on continuous risk stratifies as well as using the 33% high-risk dichotomies of the stratifiers. The trends of 
the comparisons of PE and BC6 for the prediction of NAM and AM correspond to those observed in the univar-
iate analysis.
Kaplan-Meier curves of probabilities of death, NAM, and AM for multivariate combinations between DC, PE, 
and BC6 are shown in Fig. 5.
The Figure shows that combining high risk signified by both BC6 and DC leads to a powerful prediction of 
AM. On the contrary, combination of high risk signified by both DC and PE leads to powerful prediction of 
NAM albeit the percentage level of predicted NAM is lower than that of the AM. Still, comparison of Figs. 4 and 
5 shows that addition of BC6 and PE to DC leads to meaningful increase in the predicted level of AM (in case of 
BC6 addition) and NAM (in case of PE addition) in comparison to DC alone. Besides, the addition of BC6 and 
PE also leads to strong prediction of AM.
Discussion
It is not surprising that absolute separation of AM and NAM was not achieved in our analyses. AM is caused by 
ventricular fibrillation, ventricular tachycardia or asystole/pulseless electrical activity, whereas heart failure is the 
main cause of NAM. Complex factors involved in the risk stratification give rise to a continuous risk spectrum. 
This spectrum is modulated by environmental and genetic factors and by biorhythms8,9. The determination of an 
isolated risk is further complicated by competing risk: patients at risk of AM are also subject to a risk of NAM 
and non-cardiovascular mortality. Different death modalities share risk factors such as functional status, delays 
in intraventricular conduction and concomitant atrial fibrillation10–12.
Individual risk factors, such as ventricular performance13 and abnormal autonomic regulation14,15 that appear 
immediately after an MI, change over time. In a 10-year follow-up of 120 patients with ischemic heart disease and 
LVEF < 50%, no difference was found in the cumulative incidence of AM among patients with left ventricular 
dysfunction (LVEF < 30%) and without it (>30%)16. Patients with LVEF > 30% have a good initial prognosis, but 
after 2 years of follow-up, the risk of AM increases progressively until reaching the same level of risk as patients 
with depressed left ventricular function.
New HRV parameter BC6 characterizes sinus-nodal response to physiological and pathophysiological stimuli. 
It has previously been found to progressively decrease in the presence of cardiac abnormalities5. PE is related to 
the presence of early ventricular contractions. The association of these indices with different mortality modes 
appears physiologically plausible.
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Although the application of the new HRV parameters to the placebo patients of the EMIAT trial does not seem 
to significantly improve the individual prediction of mortality, a strong relationship between BC6 and AM has 
been shown. BC6 was the only parameter able to significantly discriminate between AM and NAM.
The new HRV parameter PE, although being related with the ectopic activity, has not shown a prognostic 
capacity with AM, but with NAM, as previously reported. In heart failure the highest PE and the lowest BC6 were 
found5.
Our results indicate that the combination of different novel HRV parameters with the well-established DC 
risk indicator might contribute to the separation of AM and NAM in patients with severe ischemic heart disease. 
Since these factors are derived from Holter recordings, adding the novel HRV parameters to DC does not imply 
additional clinical burden in the process of selecting high-risk patients. Although what the new parameters add 
to DC in this limited study may appear modest in the pure multivariate statistical sense, they may contribute 
meaningfully to the practical selection of specific high-risk groups.
Limitations. There are several important limitations of this study that need to be considered. Whilst we used 
the EMIAT trial data because of the objective and independent classification of mortality modes in a relatively 
high-risk population (patients with LVEF above 40% were not enrolled), the data are historical and were obtained 
during the era of pharmacological thrombolytic treatment before the introduction of routine acute angioplasty 
procedures (almost two thirds of the patients reported in this sub-study received acute thrombolysis). It is possi-
ble if not likely that with acute angioplasty interventions, the levels of mortality risk are presently somewhat 
lowered. Nevertheless, it is also likely that the distinction between AM and NAM is presently similar to what it 
was during the EMIAT trial17. Both DC and the novel HRV parameters utilize RR interval sequences. 
Electrocardiographic recordings obviously contain further information such as on ventricular repolarization and 
on QRS abnormalities which have previously been also used for risk prediction18,19 and which could thus also be 
used in multivariate settings. The setup of the novel HRV parameters can also be further optimized. The toler-
ances θmax ,1 and max ,2θ  have been selected on the basis of those approximate minimum values below 0.25 where the 
first plateaus of the corresponding presence P(%) and the number of individuals with that presence above 10% are 
both reached. This selection has been made independently of the results obtained, but it can be subject of subse-
quent optimization in future works for risk prediction applications.
Conclusion
All retrospective analyses can naturally be only hypothesis generating. Nevertheless, the recently developed novel 
HRV methods appear to contribute to the risk prediction in severe ischemic heart disease. In particular, the novel 
technology provided, among others, two coefficients related to the breath influence on HRV and the presence of 
ectopic beats. This study has shown that their combination with a well-known risk predictor of DC can improve 
significantly the AM and NAM risk separation on patients who survive the acute phase of MI.
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